GBM is characterized by various genetic risks, such as mutations in TP53, PTEN, EGFR, and their downstream signaling pathways, and these potential molecular therapeutic targets have aroused extensive interest in research [14]. The gene discussed is PTEN; the disease is glioblastoma.